Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents

Journal of Parasitology

Volumn 90, Issue 5, 2004, Pages 1155-1162

  Walker, John ^a   Saravia, Nancy G ^a  

^a CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ANTIMONY DERIVATIVE; ANTIMONY GLUCONATE; ANTIMONY TARTRATE; BENZIMIDAZOLE DERIVATIVE; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; HOE 33342; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM; ANTIMONY; ANTIPROTOZOAL AGENT; BISBENZIMIDE; ENZYME INHIBITOR; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

PARASITE;

ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; LETHALITY; MONOCYTE; NONHUMAN; PROMASTIGOTE; ANIMAL; CELL STRAIN U937; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY;

ANIMALS; ANTIMONY; ANTIMONY POTASSIUM TARTRATE; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; BENZIMIDAZOLES; BISBENZIMIDE; CAMPTOTHECIN; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; LEISHMANIA DONOVANI; MEGLUMINE; MONOCYTES; ORGANOMETALLIC COMPOUNDS; U937 CELLS;

EID: 13844296875     PISSN: 00223395     EISSN: None     Source Type: Journal    
DOI: 10.1645/GE-3347     Document Type: Article

References (42)

1. ANDREWS, N. C., AND D. V. FALLER. 1991. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Research 19: 2499.
2. ATCHINSON, J., AND S. D. SILVEY. 1957. The generalization of probit analysis to the case of multiple responses. Biometrika 44: 131-140.
3. BELL, C. A., C. C. DYKSTRA, N. A. NAIMAN, M. CORY, T. A. FAIRLEY, AND R. R. TIDWELL. 1993. Structure-activity studies of dicationically substituted bis-benzimidazoles against Giardia lamblia: Correlation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition. Antimicrobial Agents and Chemotherapy 37: 2668-2673.
4. BERMAN, J. D., AND M. GROGL. 1988. Leishmania mexicana: Chemistry and biochemistry of sodium stibogluconate (Pentostam). Experimental Parasitology 67: 96-103.
5. _, AND D. J. WYLER. 1980. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. Journal of Infectious Diseases 142: 83.
6. BODLEY, A. L., M. W. MCGARRY, AND T. S. SHAPIRO. 1995. Drug cytotoxicity assay for African trypanosomes and Leishmania species. Journal of Infectious Diseases 172: 1157-1159.
7. _, AND T. A. SHAPIRO. 1995. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proceedings of the National Academy of Science USA 92: 3726-3730.
8. BROCCOLI, S., J.-F. MARQUIS, B. PAPADOPOULOU, M. OLIVIER, AND M. DROLET. 1999. Characterization of a Leishmania donovani gene encoding a protein that closely resembles a type IB topoisomerase. Nucleic Acids Research 27: 2745-2752.
9. BURRI C., A. L. BODLEY, AND T. A. SHAPIRO. 1996. Topoisomerases in kinetoplastids. Parasitology Today 12: 226-231.
10. CHAKRABORTY, A. K., A. GUPTA, AND H. K. MAJUMDER. 1993. A type 1 DNA topoisomerase from the kinetoplast hemoflagellate Leishmania donovani. Indian Journal of Biochemistry and Biophysics 30: 257-263.
11. _, AND H. K. MAJUMDER. 1988. Mode of action of pentavalent antimonials: Specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochemical and Biophysical Research Communications 152: 605-611.
12. CHEESMAN, S. J. 2000. The topoisomerases of protozoan parasites. Parasitology Today 16: 277-281.
13. DESJEUX, P. 2001. The increase in risk factors for leishmaniasis worldwide. Transactions of the Royal Society of Tropical Medicine Hygiene 95: 239-243.
14. DYKSTRA, C. C., D. R. MCCLERNON, L. P. ELWELL, AND R. R. TIDWELL. 1994. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells. Antimicrobial Agents and Chemotherapy 38: 1890-1898.
15. EPHROS, M. E., A. BITNUN, P. SHAKED, E. WALDMAN, AND D. ZILBERSTEIN. 1999. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrobial Agents and Chemotherapy 43: 278-282.
16. FARAULT-GAMBARELLI, F., R. PIARROUX, M. DENIAU, B. GIUSIANO, P. MARTY, G. MICHEL, B. FAUGERE, AND H. DUMON. 1997. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: A study of 37 strains collected from patients with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 41: 827-830.
17. HERWALDT, B. L. 1999. Leishmaniasis. Lancet 354: 1191-1199.
18. HOOPER, D. C. 1998. Clinical applications of quinolones. Biochiica et Biophysica Acta 1400: 45-61.
19. IBRAHIM, M. E., M. HAG-ALI, A. M. EL-HASSAN, T. G. THEANDER, AND A. KHARAZMI. 1994. Leishmania resistant to sodium stibogluconate: Drug-associated macrophage-dependent killing. Parasitology Research 80: 569-574.
20. JACKSON, J. E., J. D. TALLY, W. Y. ELLIS, Y. B. MEBRAHTU, P. G. LAWYER, J. B. WERE, S. G. REED, D. M. PANISKO, AND B. L. LIMMER. 1990. Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. from patients unresponsive to pentavalent antimony therapy. American Journal of Tropical Medicine and Hygiene 43: 464-480.
21. JHA, T. K., S. SUNDAR, C. P. THAKUR, P. BACHMANN, J. KARBWANG, C. FISCHER, A. VOSS, AND J. BERMAN. 1999. Miltefosine, an oral agent for the treatment of Indian visceral leishmaniasis. New England Journal of Medicine 341: 1795-1800.
22. LIU, L. F. 1989. DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry 58: 351-375.
23. LUCUMI, A., S. ROBLEDO, V. GAMA, AND N. G. SARAVIA. 1998. Sensitivity of Leishmania Viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNA-protein complexes. Antimicrobial Agents and Chemotherapy 42: 1990-1995.
24. MARQUIS, J.-F., M. DROLET, AND M. OLIVIER. 2003. Consequence of Hoechst 33342-mediated Leishmania DNA topoisomerase-I inhibition on parasite replication. Parasitology 126: 21-30.
25. _, D. MARKHEY, E. J. LA VOLE, AND M. OLIVIER. 2003. Effects of topoisomerases inhibitors protoberberine on Leishmania donovani growth, macrophage function and infection. Journal of Parasitology 89: 1040-1052.
26. OUELLETTE, M., AND B. PAPADOPOULOU. 1993. Mechanisms of drug resistance in Leishmania. Parasitology Today 9: 150-153.
27. PATHAK, M. K., AND T. YI. 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. Journal of Immunology 67: 3391-3397.
28. RAMAGLI, L. S., AND L. V. PODRIGUEZ. 1985. Quantitation of microgram amounts of protein in two-dimensional polyacrylamide gel electrophoresis sample buffer. Electrophoresis 6: 559-563.
29. RAY, S., B. HAZRA, B. MITTRA, A. DAS, AND H. K. MAJUMDER. 1998. Diospyrin, a bisnapthoquinone: A novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Molecular Pharmacology 54: 994-999.
30. ROBERTS, W. L., J. D. BERMAN, AND P. M. RAINEY. 1995. In vitro antileishmanial properties of tri-and pentavalent antimonial preparations. Antimicrobial Agents and Chemotherapy 39: 1234-1239.
31. _, AND P. M. RAINEY. 1993. Antileishmanial activity of sodium stibogluconate fractions. Antimicrobial Agents and Chemotherapy 37: 1842-1846.
32. SERENO, D., M. CAVALEYRA, K. ZEMKOUMI, S. MAQUAIRE, A. OUASSI, AND J.-L. LEMESRE. 1998. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate pentavalent antimony mode of action. Antimicrobial Agents and Chemotherapy 42: 3097-3102.
33. _, P. HOLZMULLER, I. MANGOT, G. CUNY, A. OUASSI, AND J.-L. LEMESRE. 2001. Antimonial-mediated DNA fragmentation in Leishmania infantum promastigotes. Antimicrobial Agents and Chemotherapy 45: 2064-2069.
34. SHAKED-MISHAN, P., N. ULRICH, M. EPHROS, AND D. ZILBERSTEIN. 2001. Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. Journal of Biological Chemistry 276: 3971-3976.
35. SHAPIRO, T. A., V. A. KLEIN, AND P. T. ENGLUND. 1989. Drug-promoted cleavage of kinetoplast DNA minicircles: Evidence for a type II topoisomerase activity in trypanosome mitochondria. Journal of Biological Chemistry 264: 4173-4178.
36. SUNDAR, S. 2001. Drug resistance in Indian visceral leishmaniasis. Tropical Medicine and International Health 6: 849-54.
37. SUNDSTROM, C., AND K. NILSSON. 1976. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). International Journal of Cancer 17: 565-577.
38. TOSH, K., S. CHEESMAN, P. HORROCKS, AND B. KILBEY. 1999. Plasmodium falciparum: Stage-related expression of topoisomerase I. Experimental Parasitology 91: 126-132.
39. TRASK, D. K., AND M. T. MULLER. 1983. Biochemical characterization of topoisomerase I purified from avian erythrocytes. Nucleic Acids Research 11: 2779-2800.
40. VAN DROSS, R. T., AND M. M. SANDERS. 2002. Molecular characterization of recombinant Pneumocystis carinii topoisomerase I: Differential interactions with human topoisomerase poisons and pentamidine. Antimicrobial Agents and Chemotherapy 46: 2145-2154.
41. VILLA, H., A. R. OTERO-MARCOS, R. M. REGUERA, R. BALANA-FOUCE, C. GARCIA-ESTRADA, Y. PEREZ-PERTEJO, B. L. TEKWANI, P. J. MYLER, K. D. STUART, M.-A. BJORNSTI, AND D. ORDONEZ. 2003. A novel active DNA topoisomerase I in Leishmania donovani. Journal of Biological Chemistry 278: 3521-3526.
42. YI, T., M. K. PATHAK, D. J. LINDNER, M. E. KETTERER, C. FARVER, AND E. C. BORDEN. 2002. Anticancer activity of sodium stibogluconate in synergy with IFNs. Journal of Immunology 169: 5978-5985.